Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry
1998

Study of Urokinase Plasminogen Activator in Breast Cancer

Sample size: 36 publication Evidence: moderate

Author Information

Author(s): S Kennedy, MJ Duffy, C Duggan, C Barnes, R Rafferty, MD Kramer

Primary Institution: Royal Victoria Eye and Ear Hospital, Dublin, Ireland

Hypothesis

The study aims to semiquantitate levels of urokinase plasminogen activator (uPA) and its receptor (uPAR) in invasive breast cancers using immunocytochemistry.

Conclusion

Both uPA and its receptor are predominantly present in stromal cells in invasive breast carcinomas, suggesting that these cells may collaborate with malignant cells to mediate metastasis.

Supporting Evidence

  • uPA was detected in 94.4% of cases in stromal cells, while malignant cell staining was found in 63.6% of samples.
  • uPAR was localized principally to stromal cells surrounding invasive breast cancer, rarely detected in cancer cells.
  • Significant correlation was found between uPA and uPAR levels in both malignant and stromal cells.

Takeaway

This study looked at a special protein involved in cancer spread and found it mostly in the support cells around the cancer, not in the cancer cells themselves.

Methodology

Breast tumor tissue was obtained and stained for uPA and uPAR using specific monoclonal antibodies, with immunoreactivity evaluated semiquantitatively.

Limitations

The study did not find significant relationships between uPA/uPAR levels and established prognostic markers like tumor size or nodal status.

Statistical Information

P-Value

0.0001

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication